| Code | CSB-RA622928MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Glembatumumab, designed to specifically bind to glycoprotein nonmetastatic melanoma protein B (GPNMB). GPNMB is a type I transmembrane glycoprotein that plays important roles in cell adhesion, migration, and tissue repair. This protein is overexpressed in various malignancies, including melanoma, breast cancer, and glioblastoma, where it contributes to tumor progression, metastasis, and immune evasion. GPNMB expression has been associated with poor prognosis in multiple cancer types and is particularly elevated in triple-negative breast cancer and uveal melanoma, making it an attractive target for cancer research and therapeutic development.
Glembatumumab is a fully humanizedized IgG2 monoclonal antibody that was developed as an antibody-drug conjugate (Glembatumumab vedotin or CDX-011) for targeted cancer therapy. This biosimilar antibody serves as a valuable research tool for investigating GPNMB biology, evaluating its role in tumor microenvironments, and studying antibody-mediated targeting mechanisms in preclinical cancer models. It enables researchers to explore GPNMB-related signaling pathways and assess potential therapeutic strategies.
There are currently no reviews for this product.